Literature DB >> 20004922

In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study.

J N King1, C Rudaz, L Borer, M Jung, W Seewald, P Lees.   

Abstract

In vitro whole blood canine assays were used to quantify the inhibitory actions of the novel non-steroidal anti-inflammatory drug (NSAID) robenacoxib on the cyclooxygenase (COX) isoenzymes, COX-1 and COX-2, in comparison with other drugs of the NSAID class. COX-1 activity was determined by measuring serum thromboxane (Tx)B(2) synthesis in blood samples allowed to clot at 37 degrees C for 1h. COX-2 activity was determined by measuring prostaglandin (PG)E(2) synthesis in blood samples incubated at 37 degrees C for 24h in the presence of lipopolysaccharide. The rank order of selectivity for inhibition of COX-2 versus COX-1 (IC(50) COX-1:IC(50) COX-2) for veterinary drugs was highest with robenacoxib (128.8) compared to deracoxib (48.5), nimesulide (29.2), S+ carprofen (17.6), meloxicam (7.3), etodolac (6.6), R- carprofen (5.8) and ketoprofen (0.88). Selectivity expressed as the clinically relevant ratio IC(20) COX-1:IC(80) COX-2 was highest for robenacoxib (19.8) compared to deracoxib (2.3), S+ carprofen (2.5), R- carprofen (2.1), nimesulide (1.8), etodolac (0.76), meloxicam (0.46) and ketoprofen (0.21). An in vivo pharmacokinetic ex vivo pharmacodynamic study in the dog established dosage and concentration-effect relationships for single oral doses of robenacoxib over the dosage range 0.5-8.0mg/kg. Values of C(max) and AUC were linearly related to dosage over the tested range. Robenacoxib did not inhibit serum TxB(2) synthesis (COX-1) ex vivo at dosages of 0.5-4.0mg/kg and produced only transient inhibition (at the 1h and 2h sampling times) at the 8mg/kg dosage. All dosages of robenacoxib (0.5-8mg/kg) produced marked, significant and dose related inhibition of PGE(2) synthesis (COX-2) ex vivo. The data demonstrate that in the dog robenacoxib is a highly selective inhibitor of the COX-2 isoform of COX, and significantly inhibits COX-2 and spares COX-1 in vivo when administered orally over the dosage range 0.5-4.0mg/kg. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20004922     DOI: 10.1016/j.rvsc.2009.11.002

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  15 in total

1.  Population pharmacokinetic analysis of blood and joint synovial fluid concentrations of robenacoxib from healthy dogs and dogs with osteoarthritis.

Authors:  Hanna E Silber; Claudia Burgener; Ingrid M Letellier; Mathieu Peyrou; Martin Jung; Jonathan N King; Philippe Gruet; Jerome M Giraudel
Journal:  Pharm Res       Date:  2010-10-05       Impact factor: 4.200

2.  Serum C-reactive protein and iron levels following gonadectomy are not modified by perioperative administration of robenacoxib to dogs.

Authors:  Verónica Vieitez; Victor López-Rámis; Rafael Barrera; Ignacio A Gómez de Segura
Journal:  Can J Vet Res       Date:  2022-01       Impact factor: 0.897

3.  Pharmacokinetic/pharmacodynamic modeling for the determination of a cimicoxib dosing regimen in the dog.

Authors:  Elisabeth C Jeunesse; Marc Schneider; Frederique Woehrle; Mathieu Faucher; Herve P Lefebvre; Pierre-Louis Toutain
Journal:  BMC Vet Res       Date:  2013-12-11       Impact factor: 2.741

4.  Safety evaluation of the interchangeable use of robenacoxib (Onsior™) tablets and solution for injection in dogs.

Authors:  Céline E Toutain; Mark C Heit; Stephen B King; Rainer Helbig
Journal:  BMC Vet Res       Date:  2017-11-28       Impact factor: 2.741

5.  Efficacy and safety of oral robenacoxib (tablet) for the treatment of pain associated with soft tissue surgery in client-owned dogs.

Authors:  Gabriele Friton; Caryn Marie Thompson; Daniela Karadzovska; Stephen King; Jonathan N King
Journal:  BMC Vet Res       Date:  2017-06-26       Impact factor: 2.741

6.  Six-month safety evaluation of robenacoxib tablets (Onsior™) in dogs after daily oral administrations.

Authors:  Céline E Toutain; Patrick Brossard; Stephen B King; Rainer Helbig
Journal:  BMC Vet Res       Date:  2018-08-17       Impact factor: 2.741

7.  Robenacoxib versus meloxicam for the management of pain and inflammation associated with soft tissue surgery in dogs: a randomized, non-inferiority clinical trial.

Authors:  Philippe Gruet; Wolfgang Seewald; Jonathan N King
Journal:  BMC Vet Res       Date:  2013-05-02       Impact factor: 2.741

8.  The effect of robenacoxib on the concentration of C-reactive protein in synovial fluid from dogs with osteoarthritis.

Authors:  David Bennett; Peter David Eckersall; Mary Waterston; Veronica Marchetti; Alessandra Rota; Eilidh McCulloch; Silvia Sbrana
Journal:  BMC Vet Res       Date:  2013-03-01       Impact factor: 2.741

9.  Efficacy and Safety of Injectable Robenacoxib for the Treatment of Pain Associated With Soft Tissue Surgery in Dogs.

Authors:  G Friton; C Thompson; D Karadzovska; S King; J N King
Journal:  J Vet Intern Med       Date:  2017-05       Impact factor: 3.333

Review 10.  Robenacoxib in the treatment of pain in cats and dogs: safety, efficacy, and place in therapy.

Authors:  Kavitha Kongara; John Paul Chambers
Journal:  Vet Med (Auckl)       Date:  2018-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.